BSA Icon

4. BIOTECH SUMMIT AUSTRIA 2026

13 – 14 Oct 2026 | Innsbruck, Austria

Register
Register
Register

EVOMEDIS GmbH

Company

www.evomedis.com/Graz, Austria
39 profile visits

About

Social media

Areas of activity

BIOLOGY / BIOTECHNOLOGY

Cellular and Molecular BiologyTherapeutic Development

THERAPEUTIC AREA

DermatologyPulmonary/Respiratory Diseases

Representatives

Head of Pre-Clinical Research

EVOMEDIS GmbH

Marketplace (5)

  • Product

    EVOCellic

    EVOCellic is a ready-to-use cell therapy, developed for promoting accelerated wound regeneration, using specially activated cells, for burn and chronic wounded patients. Its freeze-dried formulation allows for easy storage, even at higher temperatures.

    Author

    Head of Pre-Clinical Research at EVOMEDIS GmbH

    Graz, Austria

  • Product

    EVOLung

    EVOLung represents a breakthrough approach to treating inhalation injuries — a critical medical challenge with limited therapeutic options and significant unmet clinical need.

    Author

    Head of Pre-Clinical Research at EVOMEDIS GmbH

    Graz, Austria

  • Investment

    Series A investiment for Phase I/II trials

    EVOMEDIS is raising investments for a Series A round to complete two Phase I/II trials in burn and diabetic foot ulcer patients (data expected: 2029).

    Author

    Head of Pre-Clinical Research at EVOMEDIS GmbH

    Graz, Austria

  • Product

    EVOHair

    EVOHair introduces a novel regenerative approach to hair restoration by leveraging the unique biological properties of senescent cells.

    Author

    Head of Pre-Clinical Research at EVOMEDIS GmbH

    Graz, Austria

  • Product

    EVOEye

    EVOEye applies EVOCellic’s proprietary keratinocyte production technology to a new indication — the regeneration of the ocular surface following injury or disease.

    Author

    Head of Pre-Clinical Research at EVOMEDIS GmbH

    Graz, Austria